← Back to all stories
HealthBrain wired to regain lost weight

Review: Brain mechanisms treat higher past weight as normal and drive regain after loss

A 2025 Cell review by University of Copenhagen researchers describes how brain circuits evolved to defend body fat stores defend a previously higher weight after loss, increasing hunger and reducing energy use. This biological response, not simply willpower failure, helps explain common weight regain and the temporary effects of drugs like Wegovy. The findings, popularized in a The Conversation article, underscore obesity as a neurobiological condition with implications for treatment and prevention.

Key points

  • Brain defends prior higher weight as new set point after loss via hunger and metabolic changes.
  • GLP-1 drugs like Wegovy curb appetite signals but weight often returns after stopping.
  • Obesity viewed as biological condition shaped by brain, genes, and environment.
10h ago3 min read6 SourcesAI-generated — how does this work?

Why this is uncovered

Covered by The Conversation, ScienceDaily, Yahoo and select international outlets, with limited major mainstream pickup.


This article was generated automatically from primary sources and has not been reviewed by a human editor. Verify claims before sharing.

Weight loss is not merely a matter of willpower involving eating less and moving more, according to a scientific review. The human brain evolved complex defenses to protect body fat stores during periods of scarcity, and these systems can treat a previously higher body weight as the new normal after loss (The Conversation).

Researchers Valdemar Brimnes Ingemann Johansen and Christoffer Clemmensen of the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen detail this in a comprehensive review published in the journal Cell in August 2025. The paper outlines how the central nervous system controls energy homeostasis through neuroendocrine signals and neural circuits (Cell).

When weight is lost, the body responds as if facing a survival threat. Hunger hormones increase, food cravings intensify, and energy expenditure decreases. These adaptations optimized energy storage in environments with uncertain food supplies but now contribute to difficulties maintaining weight loss in settings of abundant calorie-dense food and reduced activity needs (The Conversation; Nature reviews).

The brain possesses mechanisms that effectively “remember” a prior higher weight and defend it. Once the body has been heavier, circuits treat that level as the baseline to maintain. This helps account for the frequent regain of lost weight after dieting. The response reflects evolutionary biology rather than a failure of personal discipline (Cell; The Conversation).

Medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide) offer an approach by mimicking gut hormones that signal the brain to reduce appetite. They can produce substantial weight loss in many users. However, not all individuals respond, side effects can limit adherence, and weight commonly returns when treatment ends as biological defenses reassert (The Conversation; PubMed).

The review highlights neuroplasticity and related insights as potential paths for future therapies that might more durably adjust these defensive signals. Broader research also indicates that improvements in sleep, physical activity, nutrition, and mental well-being can enhance metabolic and heart health independently of major changes on the scale (Cell; Nature).

Obesity is framed as a complex biological condition influenced by brain function, genetics, and environment rather than solely individual behavior. Genetic studies show high heritability of body mass index, with many associated variants linked to brain pathways involved in appetite. Environmental factors, including food availability, interact with these predispositions (Cell).

Prevention strategies discussed include healthier school meals, limits on junk-food marketing to children, urban design favoring walking and cycling, and attention to early-life periods from pregnancy to about age seven, when weight-regulation systems appear particularly adaptable. Parental diet, infant feeding, and early habits can influence long-term appetite and fat-storage control (The Conversation).

Sustainable habits such as prioritizing sleep to help regulate appetite and incorporating regular activity remain practical steps for individuals, even as pharmacological and societal approaches evolve. The authors note that science, medicine, and policy are beginning to address the biological drivers more directly (The Conversation).

The review synthesizes decades of evidence on brain control of energy balance and its relevance to anti-obesity treatments, building on established concepts such as set-point regulation while incorporating newer data on circuits, plasticity, and gut-brain signaling.

Share:X / TwitterLinkedIn

Want to respond?

The Uncovered has no comment section by design — we don't host or moderate discussions. If you still want to read along or join in, you can do so over Nostr, an open protocol where your replies live on your own key instead of on our server. Install NostrComments for Chrome or Firefox and the discussion appears on top of this page. Works on desktop and on Firefox for Android.

Open source, no tracking, free.

More in Health

ECDC assesses upsurge in ceftriaxone-resistant gonorrhoea with domestic transmission in EU/EEA and UK

The European Centre for Disease Prevention and Control issued a risk assessment on 16 July 2026 documenting rising cases of ceftriaxone-resistant Neisseria gonorrhoeae across Europe since 2022, including evidence of local transmission in several countries. Overall risk remains low for the general population but higher for those with multiple partners or travel-linked exposures; all reported cases have been successfully treated so far. ECDC recommends strengthened surveillance, testing, and prevention measures to preserve treatment options.

4 Aug 2026

Israeli researchers find sildenafil may restrict cancer metastasis by disrupting cholesterol trafficking

A peer-reviewed study from the Weizmann Institute of Science shows that sildenafil, the active ingredient in Viagra, can impair cancer cells' ability to metastasize by trapping cholesterol in lysosomes. Laboratory models and analysis of health records from millions of patients indicated reduced spread and improved survival, especially when combined with statins. Researchers call for clinical trials to explore potential therapeutic use.

4 Aug 2026

Daily avocado intake modestly lowers LDL particle levels linked to heart disease risk in adults with obesity

A Penn State-led ancillary analysis of a randomized trial found that adults with abdominal obesity who ate one avocado daily for six months reduced blood concentrations of LDL particles by about 49 nmol/L compared with those on their habitual diet. Researchers estimated this change corresponds to an approximate 4% lower heart disease risk, with no significant effects on weight or other lipoprotein measures.

2 Aug 2026